Item 2.02.  Results of Operations and Financial Condition.
On November 10, 2021, Axcella Health Inc., doing business as "Axcella
Therapeutics," announced its financial results for the third quarter ended
September 30, 2021. The full text of the press release issued in connection with
the announcement is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Chief Financial Officer
On November 4, 2021, Laurent Chardonnet, the Chief Financial Officer of the
Company, notified the Company of his resignation effective as of November 28,
2021. Mr. Chardonnet will be departing the Company for personal reasons and to
pursue other interests. He will continue to serve as a consultant to the Company
to ensure a smooth transition. The Company thanks Mr. Chardonnet for his
contributions and has initiated a search for a new Chief Financial Officer.
Item 9.01.  Financial Statements and Exhibits.
(d) Exhibits:
   Exhibit
     No.               Description

                         Press Release issued by Axcella Health Inc., doing business as "Axcella
     99.1              Therapeutics," dated November 10, 2021
     104               Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses